CA3068365A1 - Targeted protein degradation - Google Patents

Targeted protein degradation Download PDF

Info

Publication number
CA3068365A1
CA3068365A1 CA3068365A CA3068365A CA3068365A1 CA 3068365 A1 CA3068365 A1 CA 3068365A1 CA 3068365 A CA3068365 A CA 3068365A CA 3068365 A CA3068365 A CA 3068365A CA 3068365 A1 CA3068365 A1 CA 3068365A1
Authority
CA
Canada
Prior art keywords
car
cell
protein
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068365A
Other languages
English (en)
French (fr)
Inventor
Lewis Lee Brayshaw
Michael Menteith Hann
Christopher Herring
Carlos Martinez Fleites
Markus Alexander Queisser
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA3068365A1 publication Critical patent/CA3068365A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3068365A 2017-07-03 2018-07-02 Targeted protein degradation Pending CA3068365A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1710620.4 2017-07-03
GBGB1710620.4A GB201710620D0 (en) 2017-07-03 2017-07-03 Targeted protein degradation
PCT/EP2018/067741 WO2019007869A1 (en) 2017-07-03 2018-07-02 TARGETED DEGRADATION OF PROTEINS

Publications (1)

Publication Number Publication Date
CA3068365A1 true CA3068365A1 (en) 2019-01-10

Family

ID=59592357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068365A Pending CA3068365A1 (en) 2017-07-03 2018-07-02 Targeted protein degradation

Country Status (8)

Country Link
US (2) US10683360B2 (https=)
EP (1) EP3649149A1 (https=)
JP (1) JP7369039B2 (https=)
CN (1) CN110997710A (https=)
BR (1) BR112019028024A2 (https=)
CA (1) CA3068365A1 (https=)
GB (2) GB201710620D0 (https=)
WO (1) WO2019007869A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
JP2020533383A (ja) * 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
AU2018351050B2 (en) * 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
US12049482B2 (en) * 2017-10-31 2024-07-30 The Brigham And Women's Hospital, Inc. Molecular switch-mediated control of engineered cells
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
JP2022517566A (ja) * 2019-01-07 2022-03-09 ユニバーシティ オブ ワシントン タンパク質分解の調整可能な制御のためのタンパク質スイッチの新規設計
WO2020146254A1 (en) * 2019-01-07 2020-07-16 The Regents Of The University Of California Caged-degron-based molecular feedback circuits and methods of using the same
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
EP3959320A1 (en) * 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
JP7523541B2 (ja) * 2019-11-27 2024-07-26 ワンジーン バイオテクノロジー インコーポレイテッド 生体内における持続時間が延長された多機能性多重特異性マルチマー生体分子重合体
WO2021162394A1 (ko) * 2020-02-14 2021-08-19 충북대학교 산학협력단 B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
CN114057890A (zh) * 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
CN116368152A (zh) * 2020-09-13 2023-06-30 山东博安生物技术股份有限公司 通过受体tac技术的膜结合蛋白的下调
CN112266404A (zh) * 2020-10-28 2021-01-26 北京大学深圳研究生院 选择性修饰靶标蛋白的基团转移方法及其应用
CN112940096A (zh) * 2021-01-29 2021-06-11 西安交通大学 一种膀胱癌血清多肽标志物及其应用
WO2022161502A1 (zh) * 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
CN112980882A (zh) * 2021-03-15 2021-06-18 上海科技大学 Crbn基因在构建GSPT1敏感模型中的用途
CA3223636A1 (en) * 2021-08-06 2023-02-09 Christopher Walton CARROLL Compositions and methods for selective degradation of engineered proteins
NL2031325B1 (en) 2022-03-18 2023-09-29 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Novel zinc finger degron sequences
KR20250120279A (ko) 2022-12-01 2025-08-08 에테하 취리히 변형된 아미노산 데그론(maad)을 식별하기 위한 방법
NL2037809B1 (en) 2024-05-29 2025-12-12 Cell Control Biotherapeutics Inc Loop reinforcement expression system for improved cell therapy products
CN119699269B (zh) * 2024-07-10 2025-10-17 太原市中心医院 基于sbsn 600位赖氨酸发生二羟基异丁酰化修饰的用于银屑病研究的小鼠模型构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457095A1 (en) * 2001-08-17 2003-02-27 Toolgen, Inc. Zinc finger domain libraries
AU2012249491B2 (en) * 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
AU2013222935B2 (en) * 2012-02-24 2016-03-10 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
CN103265635A (zh) * 2013-04-28 2013-08-28 中山大学附属第一医院 一种通用的靶向蛋白嵌合型分子化合物的构建方法
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
JP2017530711A (ja) * 2014-10-10 2017-10-19 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 標的タンパク質の安定性を改変する治療法を開発するための方法
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US11168345B2 (en) * 2015-09-11 2021-11-09 The Broad Institute, Inc. Methods of identifying a polypeptide target for degradation by a modulator of CRBN
WO2017117118A1 (en) * 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
JP7100028B2 (ja) * 2016-10-20 2022-07-12 セルジーン コーポレイション セレブロン系のヘテロ二量体化可能なキメラ抗原受容体

Also Published As

Publication number Publication date
US20190002578A1 (en) 2019-01-03
US10683360B2 (en) 2020-06-16
WO2019007869A1 (en) 2019-01-10
GB2568987A (en) 2019-06-05
JP2020529970A (ja) 2020-10-15
GB201710620D0 (en) 2017-08-16
JP7369039B2 (ja) 2023-10-25
GB201810814D0 (en) 2018-08-15
US11427643B2 (en) 2022-08-30
US20200283538A1 (en) 2020-09-10
EP3649149A1 (en) 2020-05-13
CN110997710A (zh) 2020-04-10
BR112019028024A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
US11427643B2 (en) Targeted protein degradation
EP3589733B1 (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
CN110392692B (zh) 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
ES2877398T3 (es) Vectores retrovíricos y lentivíricos
JP2022522654A (ja) Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
ES2962588T3 (es) Proteínas de fusión de PD-1 y 4-1BB
TW201920247A (zh) 抗原呈現多肽及其使用方法
CA3030003A1 (en) Methods and compositions for transducing lymphocytes and regulating the activity thereof
CA2986604A1 (en) Masking chimeric antigen receptor t cells for tumor-specific activation
US20220323494A1 (en) Novel Control Switch
EP4288529A2 (en) Synthetic degrader system for targeted protein degradation
JP7404331B2 (ja) 膜結合型ＩＬ－１０をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたＴｒｅｇ
CA3019509A1 (en) Inhibition of tgfbeta in immunotherapy
CN115397867A (zh) Epcam抗体与car-t细胞
JP2021515574A (ja) 誘導性ｔ細胞レセプター及びその使用
CN115279407A (zh) 用于在哺乳动物中刺激嵌合抗原受体介导的免疫应答的方法中的包含pd-l1和/或pd-l2的靶向模块
CN115279389A (zh) 新型显性负性Fas多肽、包含其的细胞及其用途
WO2024033544A1 (en) Deglycosylation of native glycoproteins expressed on a tumor cell surface
HK1247625A1 (en) Masking chimeric antigen receptor t cells for tumor-specific activation
HK40019687A (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
HK40019687B (en) Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230703

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251218

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260218